Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Opdivo (nivolumab) Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The Opdivo (nivolumab) market has witnessed significant expansion over recent years. It is projected to increase from $8.34 million in 2025 to $9.01 million in 2026, achieving a compound annual growth rate (CAGR) of 8.1%. Key drivers behind this historic growth include the approval of PD-1 inhibitors, the escalating global cancer burden, the inherent limitations of chemotherapy, strong outcomes from clinical trials, and the growing adoption of immunotherapy by oncologists.
The market for Opdivo (nivolumab) is projected to experience considerable expansion over the coming years. By 2030, its value is anticipated to reach $12.13 million, driven by a compound annual growth rate (CAGR) of 7.7%. This upward trajectory during the forecast period is fueled by the drug’s entry into novel oncology areas, the rising prevalence of combination therapy approaches, improved patient selection based on biomarkers, higher rates of cancer detection, and increased global spending on oncology care. Key developments shaping this period include the broader application of immune checkpoint inhibitors, the growing popularity of combination immunotherapies, the surge in PD-1-targeted cancer therapies, the drug’s utilization across a wider spectrum of cancer types, and a heightened emphasis on achieving long-term survival outcomes.
Download A Free Sample Report For Comprehensive Market Insights:
Opdivo (nivolumab) Market Expansion Supported By Key Demand Factors
The growing prevalence of non-small cell lung cancer is anticipated to drive expansion in the opdivo (nivolumab) market in the coming years. As the predominant form of lung cancer, non-small cell lung cancer (NSCLC) constitutes roughly 85% of all lung cancer diagnoses. Factors such as smoking, exposure to environmental contaminants, genetic alterations, and a hereditary predisposition to cancer are key contributors to the rising frequency of NSCLC. Opdivo functions by inhibiting the PD-1 receptor on immune cells, which boosts the immune system’s ability to identify and destroy cancerous cells. In 2024, as an illustration, the American Cancer Society, a US-based health organization, noted that 234,580 new lung cancer cases were identified in the United States, with 80% classified as NSCLC, reflecting an uptick from 2023, when 238,340 individuals received a lung cancer diagnosis. Consequently, the increasing occurrence of non-small cell lung cancer is fueling growth in the opdivo (nivolumab) market.
Opdivo (nivolumab) Market Segment Landscape And Growth Potential
The opdivo (nivolumab) market covered in this report is segmented –
1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL
2) By Dosage: Injection, Solution, Other Dosages
3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications
4) By End-User: Hospitals, Clinics, Other End Users
Opdivo (nivolumab) Market Growth Trends Influencing Competitive Dynamics
Leading companies in the Opdivo (nivolumab) market are intensively working on sophisticated combination therapies designed to improve treatment effectiveness, address drug resistance, and expand usage across diverse cancer indications. Combination therapy involves the deliberate pairing of Opdivo (nivolumab) with other treatments, such as chemotherapy, to deliver a more holistic care strategy for patients with advanced malignancies. A notable example occurred in October 2024, when the U.S.-based Food and Drug Administration granted approval for Opdivo (nivolumab) combined with platinum-based chemotherapy as a neoadjuvant therapy, followed by single-agent nivolumab as postsurgical adjuvant treatment, for adults with resectable non-small cell lung cancer who lack confirmed EGFR or ALK mutations. With this regulatory nod, Opdivo can now be administered both prior to and following surgery, thereby improving clinical outcomes for suitable individuals.
Opdivo (nivolumab) Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical
Access The Complete Opdivo (nivolumab) Market Report:
Opdivo (nivolumab) Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model